Full Press Release Details
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of
- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity -
- Pharmacokinetic and safety
profile validate conditionally active approach -
- Investor webcast to be held on Monday, June 3 at 8:00 a.m. ET -
BOSTON, MA May 23, 2024 Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company
focused on the discovery and development of next-generation therapeutics for cancer patients, today reported encouraging clinical data from the dose escalation portion of its Phase 1/2 trial of SNS-101, a
conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).
I am pleased that SNS-101 has been well-tolerated in the study, reaching its highest planned dose level with no
dose limiting toxicities and demonstrating its potential to successfully overcome the prior challenges of VISTA-targeted programs, said Dr. Shiraj Sen, Medical Oncologist and Director of Clinical Research at NEXT Oncology, Dallas, and a
principal investigator for the SNS-101 study. The data show encouraging signs of clinical activity in a heterogeneous population of patients with advanced solid tumors, where you typically wouldn t
expect to see clinical responses, especially in microsatellite stable colorectal and endometrial tumors. There is a continued unmet need for patient populations that have become resistant or don t respond to current immunotherapy treatment
options. I look forward to continuing to evaluate its progress.
Dose escalation portion of the Phase 1/2 clinical trial
The dose escalation portion of the Phase 1/2 clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy
of SNS-101. This study assesses SNS-101 both as monotherapy and in combination with Regeneron s PD-1 inhibitor Libtayo (cemiplimab, 350 mg), in patients with advanced solid tumors with primary (unfavorable candidates for immunotherapy) or acquired PD-1 therapy resistance
(progressed on prior anti-PD-1 therapy).
A total of 34 patients received SNS-101 once every 3 weeks, with 16 patients in the monotherapy arm and 18 patients in the combination arm. The majority of patients (85%) had a tumor type that is typically unresponsive to PD-1 monotherapy ( cold tumors).
As of the April 30, 2024 data cutoff,
SNS-101 demonstrated preliminary evidence of promising clinical activity in multiple tumor types, including:
data are consistent with preclinical studies suggesting therapeutically relevant clinical doses of SNS-101 at 3mg/kg or higher. Additionally, preliminary flow-based pharmacodynamic analysis showed
dose-dependent changes in specific T-cell populations suggesting SNS-101 may be having a pharmacological effect on T-cell
SNS-101 demonstrated a potentially
best-in-class pharmacokinetic (PK) profile with linear elimination kinetics and dose-proportional increases in exposure, supporting once every three week dosing. The
data are consistent with lack of target-mediated drug disposition (TMDD), which has been observed in non-conditionally active anti-VISTA antibodies.
SNS-101 was well tolerated alone and in combination with cemiplimab, with no dose-limiting toxicities observed. The
majority of AEs were Grade 1 or 2 in severity. Two patients experienced Grade 1 cytokine release syndrome (CRS), one in monotherapy and one in combination, both at the highest dose of SNS-101. Both cases were
mild and manageable, demonstrating that SNS-101 has the potential to overcome a key hurdle that hindered first-generation VISTA-targeting approaches. Four patients in the combination cohort experienced
immune-mediated events. There were also no significant changes to key inflammatory cytokine levels, including interferon gamma, interleukin-6, interleukin-10, interleukin-8, TNF-alpha, and CCL5-RANTES, across cohorts.
escalation portion of the Phase 1/2 trial of SNS-101 answers the critical question of whether a pH-selective approach can overcome the previous hurdles associated with
targeting VISTA, which included severe safety and PK issues. We believe the topline data presented today marks an important milestone and validates the mechanism of action by demonstrating the potentially best-in-class PK and a well-tolerated safety profile of SNS-101 at therapeutically relevant dose levels, said Ron Weitzman, Chief Medical Officer of Sensei Bio.
We saw promising clinical activity primarily in tumor types that don t typically respond to PD-1 monotherapy and look forward to progressing through the expansion phase of the study.
Ongoing dose expansion portion of the Phase 1/2 clinical trial
Patient enrollment is advancing in the dose expansion portion of the Phase 1/2 study. The Company expects to report initial data from the dose expansion
cohorts and to hold an end-of-Phase 1 meeting with the FDA by the end of 2024.
The data will be presented in a poster
presentation entitled Initial results from a first-in-human phase 1 study of SNS-101
(pH-selective anti-VISTA antibody) alone or in combination with cemiplimab in patients with advanced solid tumors, on June 1, 2024, at the 2024 American Society of Clinical Oncology (ASCO) Annual
Meeting being held in Chicago, IL. The poster will be available on the Sensei website at the start of the poster presentation.
Sensei will host a webcast on Monday, June 3, 2024, at 8:00 a.m. ET (7:00 a.m. CT) to discuss the data. Participating alongside Company management will be
Dr. Shiraj Sen, M.D., Ph.D., Medical Oncologist and Director of Clinical Research at NEXT Oncology-Dallas. Dr. Sen is an investigator on the ongoing Phase 1/2 clinical trial for SNS-101, and lead
author of the SNS-101 poster. The live event can be assessed here: https://lifescievents.com/event/sensei/ and can be accessed on the Investor page of Sensei s website at
https://investors.senseibio.com/. A replay of the webcast will be available after the completion of the event.
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of
next-generation therapeutics for cancer patients. Through its TMAb (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to
disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. Sensei s lead investigational candidate is SNS-101, a conditionally active antibody
designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain
Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate
diphosphohydrolase-1 (ENTPDase1), also known as CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody consisting of a CD28 agonist arm and a pH-sensitive anti-VISTA arm. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by
words and phrases such as believe , designed to, expect , may , plan , potential , will , and similar expressions, and are based on Sensei s current beliefs and
expectations. These forward-looking statements include expectations regarding the development, potential therapeutic benefits and safety profile of Sensei s product candidates, including SNS-101, and the
timing of reporting data from the Phase 1/2 study of SNS-101. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.
Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Sensei s product candidates will not be
successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Sensei s product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from
preclinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Sensei s product candidates; the risk that Sensei s product candidates or procedures in connection with the
administration thereof will not have the safety or efficacy profile that Sensei anticipates; risks associated with Sensei s dependence on third-party suppliers and manufacturers, including sole source suppliers, over which Sensei may not always
have full control; risks regarding the accuracy of Sensei s estimates of expenses, capital requirements and needs for additional financing; and other risks and uncertainties that are described in Sensei s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange
Commission (SEC) on May 9, 2024 and Sensei s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based
on information available to Sensei as of the date of this release, and Sensei assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Senior Director, Investor Relations
Sensei Biotherapeutics